117 related articles for article (PubMed ID: 10777375)
1. Early hormonal therapy in prostate cancer.
Swanson GP
N Engl J Med; 2000 Apr; 342(16):1215-6. PubMed ID: 10777375
[No Abstract] [Full Text] [Related]
2. Overview consensus statement. Fifth International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer.
Garnick MB; Fair WR; Bostwick D; Debruyne F; Fourcroy J; Grignon D; Porterfield H; Sufrin G; Thrasher B; Hart C
Mol Urol; 2000; 4(3):89-92. PubMed ID: 11184767
[No Abstract] [Full Text] [Related]
3. Twenty-five year evolution of medical hormonal therapy for prostate cancer.
Moul JW
BJU Int; 2009 Jan; 103(2):145-6. PubMed ID: 19278531
[No Abstract] [Full Text] [Related]
4. [Surgical and medical treatment for localized prostate cancer].
Kawai K
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1002-5. PubMed ID: 17637535
[TBL] [Abstract][Full Text] [Related]
5. [And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)].
Miller K
MMW Fortschr Med; 2009 Jul; 151(30-33):72-3. PubMed ID: 19722471
[No Abstract] [Full Text] [Related]
6. [Neoadjuvant therapy of prostate carcinoma].
Ebert T
Praxis (Bern 1994); 1997 Nov; 86(46):1815-8. PubMed ID: 9454282
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate.
Burch PA; Loprinzi CL
J Clin Oncol; 1999 Mar; 17(3):1087-8. PubMed ID: 10071307
[No Abstract] [Full Text] [Related]
8. [Salvage radiotherapy in rising PSA after radical prostatectomy].
Carrie C; Pommier P
Cancer Radiother; 2007 Nov; 11(6-7):370-2. PubMed ID: 17869564
[TBL] [Abstract][Full Text] [Related]
9. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?
Ward JF
Nat Clin Pract Urol; 2006 Jun; 3(6):310-1. PubMed ID: 16763642
[No Abstract] [Full Text] [Related]
10. How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer.
Duchesne GM; Syme R; Howell D
J Clin Oncol; 2006 Jun; 24(18):2964; author reply 2965. PubMed ID: 16782936
[No Abstract] [Full Text] [Related]
11. [Reevaluation of MAB therapy and progress of endocrine therapy].
Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
[No Abstract] [Full Text] [Related]
12. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
Moul JW; Zlotta AR
BJU Int; 2005 Feb; 95(3):285-90. PubMed ID: 15679779
[No Abstract] [Full Text] [Related]
13. Decreasing mortality rates for prostate cancer: possible role of hormonal therapy?
Damber JE
BJU Int; 2004 Apr; 93(6):695-701. PubMed ID: 15049974
[TBL] [Abstract][Full Text] [Related]
14. Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer.
D'Amico AV
J Clin Oncol; 2010 Jun; 28(16):2651-2. PubMed ID: 20421530
[No Abstract] [Full Text] [Related]
15. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant hormonal therapy plus surgery for prostate cancer. The MSKCC experience.
Fair WR; Scher HI
Surg Oncol Clin N Am; 1997 Oct; 6(4):831-46. PubMed ID: 9309096
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant hormonal therapy for prostate cancer].
Miki T; Kamoi K
Gan To Kagaku Ryoho; 2001 Jul; 28(7):927-33. PubMed ID: 11478141
[TBL] [Abstract][Full Text] [Related]
18. Biochemical failure: role for early hormonal therapy.
Amling CL
BJU Int; 2004 Dec; 94 Suppl 3():9-10. PubMed ID: 15521886
[No Abstract] [Full Text] [Related]
19. Treatment of prostate cancer with goserelin and radiotherapy.
Schoen SS
N Engl J Med; 1997 Dec; 337(23):1693; author reply 1694. PubMed ID: 9411235
[No Abstract] [Full Text] [Related]
20. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
D'Amico AV; Saegaert T; Chen MH; Renshaw AA; George D; Oh W; Kantoff PW
Cancer; 2002 Jul; 95(2):275-80. PubMed ID: 12124826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
